ARRAY BIOPHARMA INC
ARRAY BIOPHARMA INC (ARRY): 8 pipeline candidates · ~29 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
29.2 months
D/E 0.88 · 0% dilution
Lead: Approved
8 candidates
N/A
N/A
A transparent, data-derived signal for ARRAY BIOPHARMA INCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$1.2B
Cash
$96.6M
Quarterly Burn
$44.0M
Runway
29.2 mo
Revenue
$64.7M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (8 candidates)
| Drug | Phase |
|---|---|
| arry-382 | Phase 2 |
| arry-797 | Phase 3 |
| braftovi | Approved |
| ganovo | Approved |
| ipatasertib | Phase 3 |
| larotrectinib | Phase 2 |
| mektovi | Approved |
| selumetinib | Phase 3 |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
262
Total value held
$1.23B
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 29,187,086 | $211.0M |
| vanguard capital management llc | 13,356,130 | $96.6M |
| hill city capital, lp | 12,891,300 | $93.2M |
| bnp paribas asset management holding s.a. | 9,605,177 | $69.4M |
| vanguard portfolio management llc | 8,097,536 | $58.5M |
| morgan stanley | 6,993,779 | $50.6M |
| wellington management group llp | 5,782,216 | $41.8M |
| schroder investment management group | 5,778,130 | $41.8M |
| state street corp | 4,817,911 | $34.8M |
| geode capital management, llc | 3,970,445 | $28.7M |
Showing top 10 of 262 institutional holders of ARRAY BIOPHARMA INC. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in ARRAY BIOPHARMA INC's pipeline?
ARRAY BIOPHARMA INC (ARRY) has 8 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is ARRAY BIOPHARMA INC's lead drug candidate?
ARRAY BIOPHARMA INC's most advanced tracked candidate is arry-382 (Phase 2) for cancer.
What is ARRAY BIOPHARMA INC's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, ARRAY BIOPHARMA INC has approximately 29.2 months of cash runway.
What is ARRAY BIOPHARMA INC's market capitalization?
ARRAY BIOPHARMA INC's market capitalization is approximately $1.2B.
Who is the CEO of ARRAY BIOPHARMA INC?
Mr. Kevin G. Hostetler is the chief executive officer of ARRAY BIOPHARMA INC (ARRY).
Get the full picture on ARRAY BIOPHARMA INC
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.